Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial

Clin Microbiol Infect. 2015 Sep;21(9):876.e1-4. doi: 10.1016/j.cmi.2015.05.007. Epub 2015 May 14.

Abstract

We evaluated the dynamics of innate and adaptive immunity in patients treated with combined antiretroviral therapy (cART) during primary human immunodeficiency virus infection (PHI), enrolled in a prospective randomized trial (MAIN, EUDRACT 2008-007004-29). After 48 weeks of cART, we documented a reduction in activated B cells and CD8(+) T cells. Natural killer cell and dendritic cell frequencies were measured and a decrease in CD16(+) CD56(dim) with a reciprocal rise in CD56(high) natural killer cells and an increase in myeloid and plasmacytoid dendritic cells were recorded. In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity.

Keywords: B cells; dendritic cells; immune activation; natural killer cells; primary human immunodeficiency virus type 1 infection.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adaptive Immunity*
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods
  • Cyclohexanes / administration & dosage*
  • Dendritic Cells / immunology
  • Female
  • HIV / immunology*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • Humans
  • Immunity, Innate*
  • Lymphocyte Subsets / immunology
  • Male
  • Maraviroc
  • Prospective Studies
  • Triazoles / administration & dosage*

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Triazoles
  • Maraviroc

Associated data

  • EudraCT/2008-007004-29